Delivering the Right Drug to the Right Patient

Circos Plots Depicting the Relative Frequency and Pairwise Co-Occurrence of Genetic Alterations in 500 Aml Patients in Taiwan
J Biomed Sci 27, 81 (2020).

Beyond Genetic Markers

Most pharmaceutical development strategies focus on discovering drugs to address specific genetic markers. However, genetic mutations are just one of many factors relevant to patient response. Importantly, once a treatment is started, a patient may wait months to find out if it has worked. If it has not, there is little choice but to start again with a different drug. This trial-and-error approach to treatment for life-threatening disease can cost patients time that they and their family simply cannot afford.

Responder-Focused Therapeutics

It’s good to understand how things work, but in medicine, it’s more important to know that they do work. Notable is developing novel Presponse™ therapeutics so physicians will know if their patient is likely to benefit before they commit to treatment. We know that getting the right treatment to the right patient the first time is critical to success in the fight against cancer.

Our Research

Presponse™ Therapeutics

Notable is combining existing, de-risked drugs with a proprietary predicted responder diagnostic to create novel Presponse™ therapeutics. We’re increasing the clinical response rates of our therapeutics while reducing the risk, time and cost of development by identifying and treating only those patients who are most likely to benefit.

Time to Care

  • Research

It takes an average of 15 years and $2.5 billion to develop a drug, and yet, in cancer, response rates are often very low. For example, as little as 15 percent of people living with relapsed/refractory acute myeloid leukemia (AML) respond to the current standard-of-care drugs. However, a drug doesn’t have to work for everyone to be lifesaving for someone.

One Hundred Percent Committed

  • Science

Notable is breathing new life into existing drugs that have already been vetted in clinical trials but have not been approved by the FDA. By combining these de-risked drugs with our proprietary predicted responder diagnostics, we will create novel Presponse™ therapeutics that we believe will dramatically improve outcomes for patients in need.

Predictive Medicine Platform

We begin with patients, not molecules. Our predictive medicine platform employs advanced technology to bio-simulate treatment of each patient’s cancer at the cellular level. We evaluate patient response ex vivo, at scale and at speed.

Our Science

Latest Press Releases

All Press Releases

One Hundred Percent Committed

Notable is building an innovative environment at the intersection of technology and biology. We’re one hundred percent committed to transforming the traditional concept of standard-of-care by pioneering a novel responder-focused approach to drug development.